

# CITATION REPORT

List of articles citing

**Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders**

**DOI: 10.1038/sj.ijir.3901290**

**International Journal of Impotence Research, 2005, 17, 354-8.**

**Source:** <https://exaly.com/paper-pdf/38218067/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
23	Contemporary intracavernous pharmacotherapy for erectile dysfunction in the aging male. <i>Aging Health</i> , <b>2006</b> , 2, 559-570		2
22	Bibliography. Current world literature. Reconstructive surgery. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 460-38		
21	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 449-59	2.8	33
20	Optimizing response to phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , <b>2007</b> , 4, 1-6	1.2	1
19	Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. <i>European Urology</i> , <b>2009</b> , 55, 334-47	10.2	124
18	Phosphodiesterases as Drug Targets. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> ,	3.2	20
17	Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 307-22	3.2	8
16	Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?. <i>Journal of Translational Medicine</i> , <b>2013</b> , 11, 139	8.5	9
15	Phosphodiesterase inhibitors in clinical urology. <i>Expert Review of Clinical Pharmacology</i> , <b>2013</b> , 6, 323-32	3.8	20
14	Sexual dysfunction in patients with spinal cord lesions. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2015</b> , 130, 225-45	3	24
13	Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis. <i>Sexual Medicine Reviews</i> , <b>2016</b> , 4, 257-269	5.6	14
12	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , <b>2018</b> , 35, 175-187	4.7	12
11	Les traitements oraux de la dysfonction érectile aujourd'hui, pour quel patient?. <i>Sexologies</i> , <b>2018</b> , 27, 37-46	0.5	0
10	Additional non-invasive options can be considered for erectile dysfunction when phosphodiesterase type 5 inhibitors fail. <i>Drugs and Therapy Perspectives</i> , <b>2018</b> , 34, 567-571	1.5	
9	Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. <i>International Journal of Impotence Research</i> , <b>2018</b> , 30, 203-208	2.3	16
8	Practical Approaches to Treat ED in PDE5i Nonresponders. <b>2020</b> , 11, 1202-1218		3
7	Frequency and anatomic distribution of arterial obstructions in patients with vasculogenic erectile dysfunction not responding to intracavernous prostaglandin. <i>Vasa - European Journal of Vascular Medicine</i> , <b>2021</b> , 50, 306-311	1.9	1

6	Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2036337	10.4	4
5	Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer. <i>Seminars in Preventive and Alternative Medicine</i> , <b>2006</b> , 2, 76-84		1
4	Injectable Therapies After Prostate Cancer Therapy. <b>2009</b> , 197-207		
3	Oral and non-oral combination therapy for erectile dysfunction. <i>Reviews in Urology</i> , <b>2007</b> , 9, 99-105	1	7
2	Extending the rationale of combination therapy to unresponsive erectile dysfunction. <i>Reviews in Urology</i> , <b>2007</b> , 9, 197-206	1	6
1	The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors.		2